Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis

Rashmi Kaul, Mohan Shenoy, Elzbieta Goluszko, Premkumar Christadoss

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

To analyze the impact of lack of MHC class II gene expression, and to demonstrate the direct genetic evidence for the involvement of the MHC class II gene product in the development of experimental autoimmune myasthenia gravis (EAMG), MHC class II gene-disrupted C57BL6 mutant (-/-) and EAMG- susceptible MHC class II wild-type C57BL6 mice (+/+) were evaluated for the clinical and immunopathologic manifestations of EAMG. The deficiency of MHC class II, and therefore, CD4+ T cells, completely prevented the C57BL6 MHC class II mutant (-/-) mice from mounting an autoimmune response to the nicotinic acetylcholine receptor. Further, the mutant (-/-) mice failed to show any immunopathologic and clinical manifestations of EAMG. The data unequivocally provide direct genetic evidence for the essential role of MHC class II molecules in the induction of EAMG, and rule out any pathogenic effector role for MHC class I-restricted CD8+ T cells, γδ TCR-bearing cells, or NK cells, which are intact in the MHC class II mutant mice in the induction of EAMG.

Original languageEnglish (US)
Pages (from-to)3152-3157
Number of pages6
JournalJournal of Immunology
Volume152
Issue number6
StatePublished - Mar 15 1994

Fingerprint

Autoimmune Experimental Myasthenia Gravis
MHC Class II Genes
Major Histocompatibility Complex
T-Lymphocytes
Nicotinic Receptors
Autoimmunity
Natural Killer Cells
Gene Expression

ASJC Scopus subject areas

  • Immunology

Cite this

Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. / Kaul, Rashmi; Shenoy, Mohan; Goluszko, Elzbieta; Christadoss, Premkumar.

In: Journal of Immunology, Vol. 152, No. 6, 15.03.1994, p. 3152-3157.

Research output: Contribution to journalArticle

Kaul, R, Shenoy, M, Goluszko, E & Christadoss, P 1994, 'Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis', Journal of Immunology, vol. 152, no. 6, pp. 3152-3157.
Kaul, Rashmi ; Shenoy, Mohan ; Goluszko, Elzbieta ; Christadoss, Premkumar. / Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. In: Journal of Immunology. 1994 ; Vol. 152, No. 6. pp. 3152-3157.
@article{f9c9b179c6924bc381c778299405e9f8,
title = "Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis",
abstract = "To analyze the impact of lack of MHC class II gene expression, and to demonstrate the direct genetic evidence for the involvement of the MHC class II gene product in the development of experimental autoimmune myasthenia gravis (EAMG), MHC class II gene-disrupted C57BL6 mutant (-/-) and EAMG- susceptible MHC class II wild-type C57BL6 mice (+/+) were evaluated for the clinical and immunopathologic manifestations of EAMG. The deficiency of MHC class II, and therefore, CD4+ T cells, completely prevented the C57BL6 MHC class II mutant (-/-) mice from mounting an autoimmune response to the nicotinic acetylcholine receptor. Further, the mutant (-/-) mice failed to show any immunopathologic and clinical manifestations of EAMG. The data unequivocally provide direct genetic evidence for the essential role of MHC class II molecules in the induction of EAMG, and rule out any pathogenic effector role for MHC class I-restricted CD8+ T cells, γδ TCR-bearing cells, or NK cells, which are intact in the MHC class II mutant mice in the induction of EAMG.",
author = "Rashmi Kaul and Mohan Shenoy and Elzbieta Goluszko and Premkumar Christadoss",
year = "1994",
month = "3",
day = "15",
language = "English (US)",
volume = "152",
pages = "3152--3157",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis

AU - Kaul, Rashmi

AU - Shenoy, Mohan

AU - Goluszko, Elzbieta

AU - Christadoss, Premkumar

PY - 1994/3/15

Y1 - 1994/3/15

N2 - To analyze the impact of lack of MHC class II gene expression, and to demonstrate the direct genetic evidence for the involvement of the MHC class II gene product in the development of experimental autoimmune myasthenia gravis (EAMG), MHC class II gene-disrupted C57BL6 mutant (-/-) and EAMG- susceptible MHC class II wild-type C57BL6 mice (+/+) were evaluated for the clinical and immunopathologic manifestations of EAMG. The deficiency of MHC class II, and therefore, CD4+ T cells, completely prevented the C57BL6 MHC class II mutant (-/-) mice from mounting an autoimmune response to the nicotinic acetylcholine receptor. Further, the mutant (-/-) mice failed to show any immunopathologic and clinical manifestations of EAMG. The data unequivocally provide direct genetic evidence for the essential role of MHC class II molecules in the induction of EAMG, and rule out any pathogenic effector role for MHC class I-restricted CD8+ T cells, γδ TCR-bearing cells, or NK cells, which are intact in the MHC class II mutant mice in the induction of EAMG.

AB - To analyze the impact of lack of MHC class II gene expression, and to demonstrate the direct genetic evidence for the involvement of the MHC class II gene product in the development of experimental autoimmune myasthenia gravis (EAMG), MHC class II gene-disrupted C57BL6 mutant (-/-) and EAMG- susceptible MHC class II wild-type C57BL6 mice (+/+) were evaluated for the clinical and immunopathologic manifestations of EAMG. The deficiency of MHC class II, and therefore, CD4+ T cells, completely prevented the C57BL6 MHC class II mutant (-/-) mice from mounting an autoimmune response to the nicotinic acetylcholine receptor. Further, the mutant (-/-) mice failed to show any immunopathologic and clinical manifestations of EAMG. The data unequivocally provide direct genetic evidence for the essential role of MHC class II molecules in the induction of EAMG, and rule out any pathogenic effector role for MHC class I-restricted CD8+ T cells, γδ TCR-bearing cells, or NK cells, which are intact in the MHC class II mutant mice in the induction of EAMG.

UR - http://www.scopus.com/inward/record.url?scp=0028299965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028299965&partnerID=8YFLogxK

M3 - Article

VL - 152

SP - 3152

EP - 3157

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -